BioTarget™ Scoring Tool - predict efficacy before initiating a clinical trial.

Gone are the days of predicting efficacy by drug class.

Simmunome’s BioTarget™ Scoring Tool predicts the efficacy response of inhibiting, or activating, a target by tracing the biological pathways leading to disease endpoints. We simulated disease pathways and used the protein geometric structure to calculate an efficacy score and range. Efficacy scores were compared to the observed efficacy response ranges of previously completed clinical trials – successful or not – to see how we measured up.

HER2 in Advanced Breast Cancer

Target: Human Epidermal Growth Factor Receptor 2 (HER2)

Disease: Advanced Breast Cancer

Approved Drugs: Trastuzumab

BioTarget™ Prediction: 44-67%

Observed Overall Response Rate (Ref 1): 58%

Disappointed by the poor predicted efficacy for your target?

BioTarget™ will find combinations of targets that are highly effective and surpass current standard of care.

Why is BioTarget™ superior to current methods?

This is the only too to provide both quantitative & qualitative explanations of disease pathways that are, or are not, addressed by activating or inhibiting a drug target.

BACE1 in Alzheimer’s Disease

Target: β-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1)

Disease: Alzheimer’s Disease

Approved Drugs: No approved BACE1 drugs and several others terminated due to lack of efficacy.

BioTarget™ Prediction: 0%

Observed Response Rate (Ref 2): None of the disease pathways targeting BACE1 lead to the disease endpoints. BioTarget™ clearly demonstrates BACE1 is not an effective as a drug target.